quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 21, 2026

Earnings live: Netflix stock tumbles, Johnson & Johnson falls, Halliburton and United Airlines climb

View original at finance.yahoo.com
Earnings live: Netflix stock tumbles, Johnson & Johnson falls, Halliburton and United Airlines climb The fourth quarter earnings season is picking up speed…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The digital asset platform launch marks a significant step in State Street's digital asset strategy, enabling institutions to confidently embrace tokenization as part of their core strategy

    80% confidence
  • TSMC dismissed AI bubble concerns

    80% confidence
  • For 2026, 3M expects adjusted sales growth of around 4% for full-year adjusted EPS of $8.06, with full-year operating cash flow expected to be $2.3B

    80% confidence
  • For Q1 2026, Netflix guided for an operating margin of 32.1%

    80% confidence
  • Netflix will ramp up new content in the year ahead and pause its share repurchase program given the M&A deal with Warner Bros. Discovery

    80% confidence
  • D.R. Horton reiterated full-year 2026 guidance for revenue in range of $33.5B to $35B, expecting to close 86,000 to 88,000 homes by year end

    80% confidence
  • The industrial sector has continued to see mixed signals. While some areas showed resilience, others faced continued headwinds that impacted demand and supply chains.

    80% confidence
  • 3M expects temporary charges from tariffs and stranded costs from removing PFAS materials from products

    80% confidence
  • The effectiveness of products like bank smartly, more sophisticated pricing capabilities, and significant overhaul of skills, training, digital tools and incentives, together with investments in branches drove Q4 performance

    80% confidence
  • For Q1 2026, TSMC expects revenue between $34.6B and $35.8B, with gross profit margins between 63% and 65%

    80% confidence
  • Commercial real estate loans showed modest growth after 11 quarters of decline

    80% confidence
  • ExxonMobil's CEO called Venezuelan oil investments 'uninvestable'

    80% confidence
  • Heavy manufacturing markets haven't seen declines but demand has been flat, with no year-over-year usage growth

    80% confidence
  • 2025 was an important year for 3M as the company builds a strong foundation that is reshaping operating model and driving sustainable value creation

    80% confidence
  • As of Jan. 16, 7% of S&P 500 companies have reported fourth quarter results, and Wall Street analysts estimate an 8.2% increase in earnings per share for Q4. If that holds, it would represent the 10th consecutive quarter of annual earnings growth for the index.

    80% confidence
  • Over 90% of U.S. Bancorp's clients would see a detrimental impact if a 10% credit card rate cap were enacted, and 50% would face a crushing impact

    80% confidence
  • TSMC expects 2026 revenue to increase by close to 30% year over year as artificial intelligence supports strong demand for chips

    80% confidence
  • In the last few days, the conversation around the rate cap has shifted more productively to options for customers to help them in the short term

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com